	US 12,077,602 B2
	IgG epitope and applications thereof as a drug target
Xiaoyan Qiu, Beijing (CN); Jingshu Tang, Beijing (CN); Zhi Yang, Beijing (CN); Chong Wang, Beijing (CN); Jingxuan Zhang, Beijing (CN); Hua Zhu, Beijing (CN); Zihan Geng, Beijing (CN); Yang Liu, Beijing (CN); Wenhua Jiang, Beijing (CN); and Jing Huang, Beijing (CN)
Assigned to Beijing SIG Biopharmaceutical Technology Co., Ltd., Beijing (CN)
Appl. No. 16/969,189
Filed by Beijing SIG Biopharmaceutical Technology Co., Ltd., Beijing (CN)
PCT Filed Aug. 8, 2018, PCT No. PCT/CN2018/099279 § 371(c)(1), (2) Date Aug. 11, 2020, PCT Pub. No. WO2019/153674, PCT Pub. Date Aug. 15, 2019.
Claims priority of application No. 201810146884.X (CN), filed on Feb. 12, 2018; and application No. 201810330585.1 (CN), filed on Apr. 13, 2018.
Prior Publication US 2020/0369785 A1, Nov. 26, 2020
Int. Cl. C07K 16/42 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/4283 (2013.01) [G01N 33/6854 (2013.01); C07K 2317/41 (2013.01); C07K 2317/522 (2013.01); G01N 2333/70546 (2013.01); G01N 2333/91148 (2013.01)]

4 Claims

1. A method of diagnosis of an epithelial tumor expressing a sialylated RP215-IgG, comprising:

obtaining an epithelial tumor tissue sample from a subject;

determining the presence of a sialylated RP215-IgG expression pattern in the epithelial tumor tissue using a monoclonal antibody, wherein the monoclonal antibody comprises epitope-specific site binding to a C_H1 domain of non-B cell derived IgG comprising the amino acid sequence of SEQ ID NO: 1 with an N-glycosylated sialic acid modification at an Asn162 site of the C_H1 domain and is a RP215 monoclonal antibody; and

predicting metastasis and poor prognosis of the epithelial tumor by detection of the sialylated RP215-IgG in the epithelial tumor tissue sample.